Related Experiment Video
Updated: May 6, 2026
Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria
Published on: May 8, 2013
Novel antibody-antibiotic conjugate using KRM-1657 as payload eliminates intracellular MRSA in vitro and in vivo
Shiyong Fan1, Yuefan Bai2, Qilong Li3
1National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China.
Abstract:
Staphylococcus aureus is considered to be an extracellular pathogen. However, survival of S.aureus within host cells may cause long-term colonization and clinical failure. Current treatments have poor efficacy in clearing intracellular bacteria. Antibody-antibiotic conjugates (AACs) is a novel strategy for eliminating intracellular bacteria. Herein, we use KRM-1657 as payload of AAC for the first time, and we conjugate it with anti S. aureus antibody via a dipeptide linker (Valine-Alanine) to obtain a novel AAC (ASAK-22). The ASAK-22 exhibits good in vitro pharmacokinetic properties and inhibitory activity against intracellular MRSA, with 100 μg/mL of ASAK-22 capable of eliminating intracellular MRSA to the detection limit. Furthermore, the in vivo results demonstrate that a single administration of ASAK-22 significantly reduces the bacterial burden in the bacteremia model, which is superior to the vancomycin treatment.
Insights
This study introduces ASAK-22, a novel antibody-antibiotic conjugate (AAC), for effectively clearing intracellular Staphylococcus aureus (S. aureus). ASAK-22 demonstrates superior efficacy against intracellular MRSA and in bacteremia models compared to vancomycin.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Staphylococcus aureus is primarily an extracellular pathogen, but intracellular survival can lead to persistent infections and treatment failure.
- Existing therapies show limited effectiveness in eradicating intracellular bacteria, necessitating novel treatment strategies.
- Antibody-antibiotic conjugates (AACs) represent a promising approach for targeting and eliminating intracellular pathogens.
Purpose of the Study:
- To develop and evaluate a novel antibody-antibiotic conjugate (AAC) for targeting intracellular Staphylococcus aureus.
- To assess the efficacy of the novel AAC, ASAK-22, against intracellular Methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo.
Main Methods:
- Conjugation of the antibiotic KRM-1657 with an anti-S. aureus antibody using a Valine-Alanine dipeptide linker to create ASAK-22.
- Evaluation of ASAK-22's in vitro pharmacokinetic properties and anti-MRSA activity against intracellular bacteria.
- Assessment of ASAK-22's efficacy in a murine bacteremia model, comparing it to vancomycin treatment.
Main Results:
- ASAK-22 demonstrated favorable in vitro pharmacokinetic properties.
- ASAK-22 effectively eliminated intracellular MRSA in vitro at concentrations of 100 μg/mL.
- A single dose of ASAK-22 significantly reduced bacterial burden in a bacteremia model, outperforming vancomycin.
Conclusions:
- ASAK-22 is a novel and effective AAC for combating intracellular Staphylococcus aureus infections.
- The developed AAC shows significant potential for treating persistent S. aureus colonization and bacteremia.
- ASAK-22 offers a superior therapeutic strategy compared to conventional vancomycin for specific S. aureus infections.
More Related Videos
Related Concept Videos
00:57Antibiotic Selection
01:25Mechanism of Antibiotic Resistance in MRSA
01:25Clinical Significance of Antibiotic Resistance